KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer
KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer
复制标题
KRAS 作为 II 期和 III 期结直肠癌患者不良预后的预测因子以及术后 FOLFOX 化疗的获益
DOI：
10.1016/j.molonc.2015.03.006
复制
发表时间：
2015-08-01
影响因子：
6.6
通讯作者：
Wang, Jianping
中科院分区：
文献类型：
--
作者：
Deng, Yanhong;Wang, Li;Wang, Jianping
Purpose: The ERAS gene frequently mutates in colorectal cancer (CRC). Here we investigated the prognostic and predictive role of ERAS mutation in patients with stage II or III CRC.Experimental design: A consecutive cohort of patients with stage II or III CRC from a single center database was studied. The association between KRAS status, adjuvant FOLFOX therapy, and 3-year disease-free survival (3-y DFS) was analyzed.Results: Of our 433 patients, 166 (38.3%) exhibited the ERAS mutation. Among the 190 patients who did not receive adjuvant therapy, those with ERAS mutation tumors had a worse 3-y DFS (hazard ratio [HR], 1.924; 95% confidence interval [CI], 1.078-3.435; P = 0.027). Among patients who received adjuvant chemotherapy, ERAS mutation was not correlated with worse 3-y DFS (HR, 1.083; 95% CI, 0.618-1.899; P = 0.781). Adjuvant chemotherapy improved 3-y DFS only among patients with KRAS mutant tumors (78.0% vs 69.2%) on multivariate analysis adjusted for age, stage, grade, site, vessel invasion, and carcinoembryonic antigen level (HR, 0.454; 95% CI, 0.229-0.901; P = 0.024). In contrast, there was no benefit of adjuvant chemotherapy in the ERAS wild-type group (84.3% vs 82.0%).Conclusions: KRAS mutation indicates poor prognosis. FOLFOX adjuvant chemotherapy benefits patients with stage II or III colorectal cancer with ERAS mutant tumors and is worth further investigation. (C) 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
